Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.26/9916
Título: Statement on combined hormonal contraceptives containing third or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism
Autor: Bitzer, Johannes
Amy, Jean-Jacques
Beerthuizen, Rob
Birkhäuser, Martin
Bombas, Teresa
Creinin, Mitchell
Darney, Philip D
Vicente, Lisa Ferreira
Palavras-chave: Saúde Sexual e Reprodutiva
Contracetivos Hormonais
Data: 2013
Editora: BMJ
Resumo: The controversy around the combined hormonal contraceptives (CHCs) of the so-called third (containing gestodene or desogestrel) and fourth generation (containing drospirenone, DRSP) has reached a highly emotional political dimension in which all those who are professionally responsible for women’s health are involved: the national health authorities, the pharmaceutical companies, the professional organisations, the prescribers, the media and the public (i.e. the current or potential users of CHCs). The – initially scientific – controversy has now led to a public health dispute that culminated in the decision of the French authorities to withdraw the combination containing ethinylestradiol (EE) and cyproterone acetate (CPA) from the market. The potential impact of this measure, namely the loss of confidence in all CHCs, could be quite serious.
Peer review: yes
URI: http://hdl.handle.net/10400.26/9916
DOI: doi:10.1136/jfprhc-2013-100624
Versão do Editor: http://jfprhc.bmj.com/content/39/3/156.full?sid=0c636c54-4a4e-410b-8451-278587553f24
Aparece nas colecções:DGS - Artigos Científicos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Statement_on_combined_hormonal_contracetives.pdf92,69 kBAdobe PDFVer/Abrir    Acesso Restrito. Solicitar cópia ao autor!

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.